| For: | Kak M. Rebamipide in gastric mucosal protection and healing: An Asian perspective. World J Gastrointest Pharmacol Ther 2025; 16(1): 101753 [PMID: 40094150 DOI: 10.4292/wjgpt.v16.i1.101753] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v16/i1/101753.htm |
| Number | Citing Articles |
| 1 |
Akanksha Mishra, Sairam Krishnamurthy. Design, characterization and evaluation of a novel dosage form of rebamipide as transdermal patches in rodent model of Parkinson’s disease. Prospects in Pharmaceutical Sciences 2026; doi: 10.56782/pps.650
|
| 2 |
Yasir Qasim Almajidi, Maher Abdulrazzaq Al-Hakeem, Ahmed Yaseen. In Silico Preformulation Modeling, Solubility Enhancement, and Sustainable Release of Rebamipide Utilizing Deep Eutectic Mixture Loaded Bioadhesive Controlled Release Granules for Gastritis Treatment. Pharmaceutics 2026; 18(5): 521 doi: 10.3390/pharmaceutics18050521
|
| 3 |
Igor V. Maev, Alsu R. Khurmatullina, Dmitrii N. Andreev, Andrew V. Zaborovsky, Yury A. Kucheryavyy, Philipp S. Sokolov, Petr A. Beliy. Rebamipide as an Adjunctive Therapy for Gastrointestinal Diseases: An Umbrella Review. Pharmaceuticals 2026; 19(1): 144 doi: 10.3390/ph19010144
|
| 4 |
Jiaying Liu, Qingyun Chu, Renjie Li, Yifei Zhang, Ruilin Xie, Dake Chu, Jinjin Chen, Bin Gong, Yilong Cheng, Xuesi Chen. Endoscopically Deliverable Polymer Adhesives with pH-Triggered Multiple Molecular Evolution for Gastric Ulcer Repair. Journal of the American Chemical Society 2026; 148(18): 19351 doi: 10.1021/jacs.6c04947
|
| 5 |
Chenyu Zou, Yu Cao, Juxiong Liu, Xian Dong, Junlong Bi, Wenjin Guo, Shoupeng Fu. Confronting bacterial mastitis: From pathogen diversity to sustainable control in the post-antibiotic era. Animals and Zoonoses 2026; 2(1): 48 doi: 10.1016/j.azn.2025.07.004
|
| 6 |
Hebatallah H. Abo Nahas, Abdullah Al-Dakhil, Doaa I. Mohamed, Tarek A. Yousef, Ali H. Abu Almaaty, Ibrahium M. El-Deen, Hatem Adel M. Sembawa, Essa M. Saied. Rebamipide Reprograms Hepatic Networks to Prevent and Reverse Metabolic-Dysfunction-Associated Steatotic Liver Disease: Multi-Omics Insights and Histological Validation. Pharmaceuticals 2026; 19(4): 559 doi: 10.3390/ph19040559
|
| 7 |
Dong Kyung Chang, Kyunga Kim, Young-Ho Kim, Sung Noh Hong, Eun Ran Kim, Ji Eun Kim, Sang Ah Chi, Minjee Kim. Optimal strategies for mitigating gastrointestinal bleeding in patients receiving antiplatelet therapy: Real-world study. World Journal of Gastroenterology 2026; 32(14): 115790 doi: 10.3748/wjg.v32.i14.115790
Abstract(105) |
Core Tip(84) |
Full Article(HTML)(428)
|
Full Article with Cover (PDF)-1245K(26)
|
Audio-247K(6)
|
Peer-Review Report-217K(18)
|
Answering Reviewers-241K(15)
|
Supplementary Material-256K(20)
|
Full Article (PDF)-917K(68)
|
Full Article (XML)-165K(18)
|
Times Cited (0)
|
Total Visits (2622)
|
Open
|
| 8 |
Hye-Sun Lim, Gunhyuk Park. Targeting the NLRP3–NEK7 axis with rebamipide: Drug repurposing in Parkinson’s disease. Neural Regeneration Research 2026; 21(9): 4239 doi: 10.4103/NRR.NRR-D-25-01189
|
| 9 |
Nagla A. El-Shitany, Nageh Ahmed El-Mahdy, Ola Mahmoud Waly, Aya Hassan El-Kadem. Rebamipide modulates the miR-29a/SIRT1/FoxO3a and NF-κB pathways in methotrexate-induced testicular damage. European Journal of Pharmacology 2025; 1005: 178063 doi: 10.1016/j.ejphar.2025.178063
|
| 10 |
Jaewon Park, Kyoung Yul Seo, Hyunmin Ahn, Yearim Shin, Ikhyun Jun, Tae-im Kim, Bum Kyu Shin, Da-Young Yoon, Soo-Min Lee. Efficacy and Safety of SA001 in Patients with Primary Sjögren’s Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. Pharmaceuticals 2026; 19(1): 189 doi: 10.3390/ph19010189
|
| 11 |
Hyejoo Lee, Na Rae Lim, Seonwoo Kim, Hyun Cho, Woo Chul Chung. Comparative Efficacy and Safety of Stillen® and Rebamipide in Patients with Acute or Chronic Gastritis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. Journal of Clinical Medicine 2025; 14(17): 6209 doi: 10.3390/jcm14176209
|